THERAPY DOSSIER · th-064b1f40fbc0

IL-17A neutralising antibody, with genetic IL-17A deletion and Paneth cell depletion as comparators

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 9

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02662985 ↗PHASE3completed

Secukinumab and joint inflammation by power Doppler ultrasonography in active psoriatic arthritis

Psoriatic Arthritis

Enrolment: 166 · Results not recorded

NCT01377012 ↗PHASE3completed

Secukinumab in active rheumatoid arthritis with inadequate response to anti-TNF agents

Rheumatoid Arthritis

Enrolment: 637 · Results not recorded

NCT05975268 ↗PHASE3completed

Phase 3 JS005 (anti-IL-17A monoclonal antibody) in moderate to severe chronic plaque psoriasis

Moderate to Severe Chronic Plaque Psoriasis

Enrolment: 747 · Results not recorded

NCT06945107 ↗PHASE3active not recruiting

Phase 3 switching to picankibart after inadequate response to IL-17 monoclonal antibody therapy

Plaque Psoriasis

Enrolment: 308 · Results not recorded

NCT00809614 ↗PHASE2completed

Proof-of-concept study of AIN457 (secukinumab, anti-IL-17A) in psoriatic arthritis

Psoriatic Arthritis

Enrolment: 42 · Results not recorded

NCT01433250 ↗PHASE2completed

Open label extension of AIN457 (secukinumab) in relapsing-remitting multiple sclerosis

Multiple Sclerosis

Enrolment: 39 · Results not recorded

NCT07449156 ↗PHASE1/PHASE2not yet recruiting

Phase 1/2 HB0043 (IL-17A/IL-36R bispecific antibody) in moderate to severe acne vulgaris

Acne Vulgaris

Enrolment: 21 · Results not recorded

NCT06895499 ↗PHASE1/PHASE2recruiting

Phase 1/2 HB0043 (IL-17A/IL-36R bispecific antibody) in moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa

Enrolment: 15 · Results not recorded

NCT06802848 ↗NAnot yet recruiting

Real-world study of xeligekimab (anti-IL-17A) in moderate to severe plaque psoriasis

Plaque Psoriasis · Psoriatic Arthritis

Enrolment: 1000 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23125155 ↗2012Reported benefit

Critical role of interleukin-17A in murine intestinal ischemia-reperfusion injury.

MouseIschaemia-reperfusionIntestinal / mesentericC57BL/6 and IL-17A knockout mice

Model: Intestinal ischaemia-reperfusion produced by 30 minutes of superior mesenteric artery occlusion

Genetic deletion of IL-17A or treatment with an IL-17A neutralising antibody markedly reduced intestinal ischaemia-reperfusion injury and subsequent liver and kidney dysfunction, and Paneth cell depletion produced similar protection with lower IL-17A levels.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…